David Portnoy Reports Multiple CCEL Purchases and Option Holdings
Rhea-AI Filing Summary
David I. Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company’s common stock and discloses outstanding stock options. Between 08/25/2025 and 08/27/2025 Portnoy purchased several lots through retirement accounts, including 4,500 shares at a weighted average $4.65, 5,000 shares at $4.65, 11,101 shares at $4.44, 7,860 shares at $4.42, 4,500 shares at a weighted $4.53, and 6,218 shares at $4.44. The Form 4 lists numerous indirect holdings (by 401k, IRA, spouse, LLCs and corporations) and multiple outstanding stock options with exercise prices ranging from $4.30 to $12.27 covering named share amounts up to 280,000 shares for the $12.27 option.
Positive
- Insider purchases disclosed: Multiple open-market acquisitions by the Chairman/Co-CEO between 08/25/2025 and 08/27/2025 at prices between $4.42 and $4.65.
- Detailed option disclosure: The Form 4 lists exercise prices, vesting schedules and large option positions (including a 280,000-share grant at $12.27), aiding dilution analysis.
- Clear indirect ownership notes: Footnotes explain holdings through 401(k), IRA, partnerships, corporations, spouse and custodial accounts, improving transparency.
Negative
- No aggregate total reported: The filing does not present a single consolidated total of all common shares beneficially owned after transactions, requiring manual aggregation.
- Purchases via retirement accounts: Many purchases were made through 401(k) and IRA accounts, which can limit inference about proactive insider accumulation behavior compared with direct purchases.
Insights
TL;DR: Insider purchases over three days signal increased insider buying but are executed via retirement vehicles; impact appears modest relative to material corporate events.
The filing documents multiple small-to-mid-size open-market purchases by a principal executive using 401(k) and IRA accounts at prices between $4.42 and $4.65, suggesting routine accumulation rather than a single large block trade. The report also catalogs substantial option grants and exercisable options with strikes from $4.30 to $12.27, including a large grant exercisable into 280,000 shares, which is relevant for potential dilution analysis. Overall this is informative for shareholding and dilution modeling but does not disclose revenue, earnings, or corporate guidance.
TL;DR: Multiple transactions and broad indirect holdings underscore complex insider ownership; disclosure appears complete and compliant.
The Form 4 identifies direct purchases and a wide range of indirect beneficial ownership through family, partnerships and controlled entities, plus a schedule of outstanding option grants with vesting conditions disclosed. Explanatory footnotes clarify vesting triggers and the nature of indirect ownership. From a governance perspective the filing supplies necessary transparency on insider positions and option terms but does not indicate any change in control or extraordinary related-party transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 7,860 | $4.42 | $35K |
| Purchase | Common Stock | 6,218 | $4.44 | $28K |
| Purchase | Common Stock | 11,101 | $4.44 | $49K |
| Purchase | Common Stock | 4,500 | $4.65 | $21K |
| Purchase | Common Stock | 5,000 | $4.65 | $23K |
| Purchase | Common Stock | 4,500 | $4.53 | $20K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.55, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.36 to $4.46, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.44, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares of Common Stock held by Partner Community, as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.
